Shots:
- The US FDA has approved Ranluspec (ranibizumab-hkdz), a biosimilar version of Lucentis (ranibizumab)
- Ranluspec is an interchangeable ranibizumab biosimilar approved in the US, available in both vials and PFS at 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL) strengths, matching Lucentis
- It is a recombinant humanized IgG1 mAb fragment that inhibits VEGF-A and is indicated for wet age-related macular degeneration, retinal vein occlusion-related macular edema, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization
Ref: Lupin | Image: Lupin | Press Release
Related News: Lupin and Sandoz Receive the EC approval for Ranluspec (Biosimilar, Lucentis)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
